Company Overview and News

29
Enphase Energy to Buy SunPower's Microinverter Business

2018-06-13 zacks
On a definitive agreement with SunPower Corporation (SPWR - Free Report) , Enphase Energy (ENPH - Free Report) has agreed to acquire the former’s microinverter business segment for a total purchase consideration of $25 million in cash along with 7.5 million shares of the company. The acquisition is expected to be closed by the end of third-quarter 2018, subject to fulfillment of product qualification and other various conditions, mentioned in definitive asset purchase agreement.
AEE SPWR WEC 5GD SRGRF ENPH CPK

7
Enphase Energy Jumps on SunPower Microinverter Acquisition

2018-06-13 247wallst
Enphase Energy, Inc. (NASDAQ: ENPH) saw shares up sharply on Wednesday after the firm announced that it would be acquiring SunPower Corp.’s (NASDAQ: SPWR) microinverter business. The transaction is expected to close at the end of the third quarter of 2018.
SPWR 5GD SRGRF ENPH

7
Enphase Energy to Acquire SunPower’s Microinverter Business

2018-06-12 globenewswire
5-Year Agreement Expected to Accelerate Global Adoption of AC Modules as the De Facto Residential Solution
SPWR 5GD SRGRF ENPH

112
Top Analyst Upgrades and Downgrades: Altria, ConocoPhillips, First Data, Match Group, NXP Semiconductor, Seattle Genetics and More

2018-06-11 247wallst
The futures are trading slightly higher Monday morning as investors are hoping for another solid week like the one the markets produced last week, when both the NASDAQ and the Russell 2000 hit new all-time highs. With the second quarter starting to wind down, some of the companies that will be reporting in July could start releasing earnings warnings, so it pays to stay alert now.
SGEN PK WFCNP APA SPWR XEC DTE NXPI WFC.PRL 5GD DTJ WFC.PRJ COP WFC.PRT MTCH WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX KOS WFC.PRW WFC.PRV MO FRAC WFC WFC.WS OLN INCY SRGRF OAS DTW DTV FDC EEFT TRI SEMG DTY

8
Why Is SunPower (SPWR) Down 7.1% Since its Last Earnings Report?

2018-06-07 zacks
It has been about a month since the last earnings report for SunPower Corporation (SPWR - Free Report) . Shares have lost about 7.1% in that time frame.
SPWR TBPH 5GD SRGRF

9
Billions in US solar projects have been shelved after Trump panel tariff

2018-06-07 cnbc
President Donald Trump's tariff on imported solar panels has led U.S. renewable energy companies to cancel or freeze investments of more than $2.5 billion in large installation projects, along with thousands of jobs, the developers told Reuters.
SOJA SO GAPWP GPJ SPWR 5GD SRGRF FSLR GPE.PRA GPJA GPEPRA

10
First Solar, Inc. Gets Major Downgrades -- So Now What? | InvestorPlace

2018-06-07 investorplace
It’s been a downright terrible week for First Solar, Inc. (NASDAQ:FSLR), with the shares off more than 20%. And various other companies in the sector have also come under pressure like ReneSola Ltd. (ADR)(NYSE:SOL), Hanwha Q Cells Co Ltd -ADR (NASDAQ:HQCL) and SunPower Corporation (NASDAQ:SPWR).
SPWR 5GD SRGRF SOL FSLR HQCL

9
RPT-INSIGHT-Billions in U.S. solar projects shelved after Trump panel tariff

2018-06-07 reuters
June 7 (Reuters) - President Donald Trump’s tariff on imported solar panels has led U.S. renewable energy companies to cancel or freeze investments of more than $2.5 billion in large installation projects, along with thousands of jobs, the developers told Reuters.
SOJA SO GAPWP GPJ SPWR 5GD SRGRF FSLR GPE.PRA GPJA GPEPRA

9
Billions in US solar projects shelved after Trump panel tariff - Channel NewsAsia

2018-06-07 channelnewsasia
President Donald Trump’s tariff on imported solar panels has led U.S. renewable energy companies to cancel or freeze investments of more than US$2.5 billion in large installation projects, along with thousands of jobs, the developers told Reuters.
SOJA SO GAPWP GPJ SPWR 5GD SRGRF FSLR GPE.PRA GPJA GPEPRA

9
Billions in U.S. solar projects shelved after Trump panel tariff

2018-06-07 reuters
(Reuters) - President Donald Trump’s tariff on imported solar panels has led U.S. renewable energy companies to cancel or freeze investments of more than $2.5 billion in large installation projects, along with thousands of jobs, the developers told Reuters.
SOJA SO GAPWP GPJ SPWR 5GD SRGRF FSLR GPE.PRA GPJA GPEPRA

11
Global solar forecasts lowered as China cuts support policies

2018-06-06 reuters
(Reuters) - China’s unexpected move to slash incentives for solar power has sent stocks into a free fall and prompted analysts to lower forecasts for global installations this year amid expectations that a glut of excess panels would send prices tumbling.
YGE SPWR 5GD SRGRF FSLR CSIQ

664
Enphase Energy Appoints New Chief Financial Officer

2018-06-04 globenewswire
PETALUMA, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ:ENPH), a global energy technology company and the world’s leading supplier of solar microinverters, announced that Eric Branderiz has been appointed Vice President and Chief Financial Officer effective today. Mr. Branderiz succeeds Bert Garcia, who will support the orderly transition of duties through June 30, 2018.
SPWR 5GD SRGRF AMD ENPH

13
Canadian Solar (CSIQ) Q1 Earnings: What's in the Offing?

2018-05-14 zacks
Canadian Solar Inc. (CSIQ - Free Report) is set to report first-quarter 2018 results on May 16, before the market opens.
SPWR KEP 5GD SRGRF ENPH FSLR CSIQ

53
Short Sellers Getting Out of Solar, Alt Energy Stocks

2018-05-10 247wallst
Short interest moves among solar and alternative energy stocks were mixed during the two-week reporting period that ended on April 30. Of the companies we watch, short interest fell on two of three solar stocks and fell on three of four alternative energy stocks.
SPWR CLNE FCELB 5GD SRGRF PEIX FSLR CSIQ PLUG FCEL

13
SunPower (SPWR) Q1 Loss Narrower Than Expected, Sales Top

2018-05-09 zacks
SunPower Corp. (SPWR - Free Report) incurred first-quarter 2018 adjusted loss of 20 cents per share, which came in narrower than the Zacks Consensus Estimate loss of 34 cents. In the year-ago quarter, the company reported loss of 36 cents per share. Excluding one-time adjustments, the company incurred a GAAP loss of 83 cents per share, narrower than the year-ago loss of $1.58. Operational Results During the quarter, SunPower reported adjusted revenues of $399 million, surpassing the Zacks Consensus Estimate of $340 million by 17.
SPWR 5GD SRGRF ENPH FSLR CSIQ

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...